Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human <italic>Mycobacterium tuberculosis</italic> CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide Library</title><author><name sortKey="Lewinsohn, David M" sort="Lewinsohn, David M" uniqKey="Lewinsohn D" first="David M." last="Lewinsohn">David M. Lewinsohn</name><affiliation><nlm:aff id="aff1"><addr-line>Division of Pulmonary and Critical Care Medicine, Oregon Health and Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><addr-line>Portland Veterans Administration Medical Center, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Swarbrick, Gwendolyn M" sort="Swarbrick, Gwendolyn M" uniqKey="Swarbrick G" first="Gwendolyn M." last="Swarbrick">Gwendolyn M. Swarbrick</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Pediatrics, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Cansler, Meghan E" sort="Cansler, Meghan E" uniqKey="Cansler M" first="Meghan E." last="Cansler">Meghan E. Cansler</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Pediatrics, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Null, Megan D" sort="Null, Megan D" uniqKey="Null M" first="Megan D." last="Null">Megan D. Null</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Pediatrics, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Rajaraman, Veena" sort="Rajaraman, Veena" uniqKey="Rajaraman V" first="Veena" last="Rajaraman">Veena Rajaraman</name><affiliation><nlm:aff id="aff2"><addr-line>Portland Veterans Administration Medical Center, Portland, Oregon</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff4"><addr-line>Oregon Cancer Institute, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Frieder, Marisa M" sort="Frieder, Marisa M" uniqKey="Frieder M" first="Marisa M." last="Frieder">Marisa M. Frieder</name><affiliation><nlm:aff id="aff1"><addr-line>Division of Pulmonary and Critical Care Medicine, Oregon Health and Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><addr-line>Portland Veterans Administration Medical Center, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Sherman, David R" sort="Sherman, David R" uniqKey="Sherman D" first="David R." last="Sherman">David R. Sherman</name><affiliation><nlm:aff id="aff5"><addr-line>Seattle Biomedical Research Institute, Seattle, Washington</addr-line></nlm:aff></affiliation></author><author><name sortKey="Mcweeney, Shannon" sort="Mcweeney, Shannon" uniqKey="Mcweeney S" first="Shannon" last="Mcweeney">Shannon Mcweeney</name><affiliation><nlm:aff id="aff4"><addr-line>Oregon Cancer Institute, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lewinsohn, Deborah A" sort="Lewinsohn, Deborah A" uniqKey="Lewinsohn D" first="Deborah A." last="Lewinsohn">Deborah A. Lewinsohn</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Pediatrics, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23805289</idno><idno type="pmc">3689843</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689843</idno><idno type="RBID">PMC:3689843</idno><idno type="doi">10.1371/journal.pone.0067016</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">001078</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001078</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Human <italic>Mycobacterium tuberculosis</italic> CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide Library</title><author><name sortKey="Lewinsohn, David M" sort="Lewinsohn, David M" uniqKey="Lewinsohn D" first="David M." last="Lewinsohn">David M. Lewinsohn</name><affiliation><nlm:aff id="aff1"><addr-line>Division of Pulmonary and Critical Care Medicine, Oregon Health and Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><addr-line>Portland Veterans Administration Medical Center, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Swarbrick, Gwendolyn M" sort="Swarbrick, Gwendolyn M" uniqKey="Swarbrick G" first="Gwendolyn M." last="Swarbrick">Gwendolyn M. Swarbrick</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Pediatrics, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Cansler, Meghan E" sort="Cansler, Meghan E" uniqKey="Cansler M" first="Meghan E." last="Cansler">Meghan E. Cansler</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Pediatrics, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Null, Megan D" sort="Null, Megan D" uniqKey="Null M" first="Megan D." last="Null">Megan D. Null</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Pediatrics, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Rajaraman, Veena" sort="Rajaraman, Veena" uniqKey="Rajaraman V" first="Veena" last="Rajaraman">Veena Rajaraman</name><affiliation><nlm:aff id="aff2"><addr-line>Portland Veterans Administration Medical Center, Portland, Oregon</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff4"><addr-line>Oregon Cancer Institute, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Frieder, Marisa M" sort="Frieder, Marisa M" uniqKey="Frieder M" first="Marisa M." last="Frieder">Marisa M. Frieder</name><affiliation><nlm:aff id="aff1"><addr-line>Division of Pulmonary and Critical Care Medicine, Oregon Health and Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><addr-line>Portland Veterans Administration Medical Center, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Sherman, David R" sort="Sherman, David R" uniqKey="Sherman D" first="David R." last="Sherman">David R. Sherman</name><affiliation><nlm:aff id="aff5"><addr-line>Seattle Biomedical Research Institute, Seattle, Washington</addr-line></nlm:aff></affiliation></author><author><name sortKey="Mcweeney, Shannon" sort="Mcweeney, Shannon" uniqKey="Mcweeney S" first="Shannon" last="Mcweeney">Shannon Mcweeney</name><affiliation><nlm:aff id="aff4"><addr-line>Oregon Cancer Institute, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lewinsohn, Deborah A" sort="Lewinsohn, Deborah A" uniqKey="Lewinsohn D" first="Deborah A." last="Lewinsohn">Deborah A. Lewinsohn</name><affiliation><nlm:aff id="aff3"><addr-line>Department of Pediatrics, Oregon Health & Sciences University, Portland, Oregon</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">PLoS ONE</title><idno type="eISSN">1932-6203</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Identification of CD8<sup>+</sup> T cell antigens/epitopes expressed by human pathogens with large genomes is especially challenging, yet necessary for vaccine development. Immunity to tuberculosis, a leading cause of mortality worldwide, requires CD8<sup>+</sup> T cell immunity, yet the repertoire of CD8 antigens/epitopes remains undefined. We used integrated computational and proteomic approaches to screen 10% of the <italic>Mycobacterium tuberculosis</italic> (Mtb) proteome for CD8 Mtb antigens. We designed a weighting schema based upon a Multiple Attribute Decision Making:framework to select 10% of the Mtb proteome with a high probability of containing CD8<sup>+</sup> T cell epitopes. We created a synthetic peptide library consisting of 15-mers overlapping by 11 aa. Using the interferon-γ ELISPOT assay and Mtb-infected dendritic cells as antigen presenting cells, we screened Mtb-specific CD8<sup>+</sup> T cell clones restricted by classical MHC class I molecules (MHC class Ia molecules), that were isolated from Mtb-infected humans, against this library. Three novel CD8 antigens were unambiguously identified: the EsxJ family (Rv1038c, Rv1197, Rv3620c, Rv2347c, Rv1792), PE9 (Rv1088), and PE_PGRS42 (Rv2487c). The epitopes are B5701-restricted EsxJ<sub>24–34</sub>, B3905-restricted PE9<sub>53–67</sub>, and B3514-restricted PE_PGRS42<sub>48–56</sub>, respectively. The utility of peptide libraries in identifying unknown epitopes recognized by classically restricted CD8<sup>+</sup> T cells was confirmed, which can be applied to other intracellular pathogens with large size genomes. In addition, we identified three novel Mtb epitopes/antigens that may be evaluated for inclusion in vaccines and/or diagnostics for tuberculosis.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Lewinsohn, Da" uniqKey="Lewinsohn D">DA Lewinsohn</name></author><author><name sortKey="Gold, Mc" uniqKey="Gold M">MC Gold</name></author><author><name sortKey="Lewinsohn, Dm" uniqKey="Lewinsohn D">DM Lewinsohn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Day, Cl" uniqKey="Day C">CL Day</name></author><author><name sortKey="Shea, Ak" uniqKey="Shea A">AK Shea</name></author><author><name sortKey="Altfeld, Ma" uniqKey="Altfeld M">MA Altfeld</name></author><author><name sortKey="Olson, Dp" uniqKey="Olson D">DP Olson</name></author><author><name sortKey="Buchbinder, Sp" uniqKey="Buchbinder S">SP Buchbinder</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Flynn, Jl" uniqKey="Flynn J">JL Flynn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barnes, Pf" uniqKey="Barnes P">PF Barnes</name></author><author><name sortKey="Bloch, Ab" uniqKey="Bloch A">AB Bloch</name></author><author><name sortKey="Davidson, Pt" uniqKey="Davidson P">PT Davidson</name></author><author><name sortKey="Snider, De" uniqKey="Snider D">DE Snider</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oldstone, Mb" uniqKey="Oldstone M">MB Oldstone</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Woodworth, Js" uniqKey="Woodworth J">JS Woodworth</name></author><author><name sortKey="Behar, Sm" uniqKey="Behar S">SM Behar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lalvani, A" uniqKey="Lalvani A">A Lalvani</name></author><author><name sortKey="Brookes, R" uniqKey="Brookes R">R Brookes</name></author><author><name sortKey="Wilkinson, Rj" uniqKey="Wilkinson R">RJ Wilkinson</name></author><author><name sortKey="Malin, As" uniqKey="Malin A">AS Malin</name></author><author><name sortKey="Pathan, Aa" uniqKey="Pathan A">AA Pathan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lewinsohn, Dm" uniqKey="Lewinsohn D">DM Lewinsohn</name></author><author><name sortKey="Zhu, L" uniqKey="Zhu L">L Zhu</name></author><author><name sortKey="Madison, Vj" uniqKey="Madison V">VJ Madison</name></author><author><name sortKey="Dillon, Dc" uniqKey="Dillon D">DC Dillon</name></author><author><name sortKey="Fling, Sp" uniqKey="Fling S">SP Fling</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lewinsohn, Da" uniqKey="Lewinsohn D">DA Lewinsohn</name></author><author><name sortKey="Winata, E" uniqKey="Winata E">E Winata</name></author><author><name sortKey="Swarbrick, Gm" uniqKey="Swarbrick G">GM Swarbrick</name></author><author><name sortKey="Tanner, Ke" uniqKey="Tanner K">KE Tanner</name></author><author><name sortKey="Cook, Ms" uniqKey="Cook M">MS Cook</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cho, S" uniqKey="Cho S">S Cho</name></author><author><name sortKey="Mehra, V" uniqKey="Mehra V">V Mehra</name></author><author><name sortKey="Thoma Uszynski, S" uniqKey="Thoma Uszynski S">S Thoma-Uszynski</name></author><author><name sortKey="Stenger, S" uniqKey="Stenger S">S Stenger</name></author><author><name sortKey="Serbina, N" uniqKey="Serbina N">N Serbina</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grotzke, Je" uniqKey="Grotzke J">JE Grotzke</name></author><author><name sortKey="Lewinsohn, Dm" uniqKey="Lewinsohn D">DM Lewinsohn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gold, Mc" uniqKey="Gold M">MC Gold</name></author><author><name sortKey="Cerri, S" uniqKey="Cerri S">S Cerri</name></author><author><name sortKey="Smyk Pearson, S" uniqKey="Smyk Pearson S">S Smyk-Pearson</name></author><author><name sortKey="Cansler, Me" uniqKey="Cansler M">ME Cansler</name></author><author><name sortKey="Vogt, Tm" uniqKey="Vogt T">TM Vogt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lewinsohn, Dm" uniqKey="Lewinsohn D">DM Lewinsohn</name></author><author><name sortKey="Bement, Tt" uniqKey="Bement T">TT Bement</name></author><author><name sortKey="Xu, J" uniqKey="Xu J">J Xu</name></author><author><name sortKey="Lynch, Dh" uniqKey="Lynch D">DH Lynch</name></author><author><name sortKey="Grabstein, Kh" uniqKey="Grabstein K">KH Grabstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lewinsohn, Da" uniqKey="Lewinsohn D">DA Lewinsohn</name></author><author><name sortKey="Heinzel, As" uniqKey="Heinzel A">AS Heinzel</name></author><author><name sortKey="Gardner, Jm" uniqKey="Gardner J">JM Gardner</name></author><author><name sortKey="Zhu, L" uniqKey="Zhu L">L Zhu</name></author><author><name sortKey="Alderson, Mr" uniqKey="Alderson M">MR Alderson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoang, Tt" uniqKey="Hoang T">TT Hoang</name></author><author><name sortKey="Nansen, A" uniqKey="Nansen A">A Nansen</name></author><author><name sortKey="Roy, S" uniqKey="Roy S">S Roy</name></author><author><name sortKey="Billeskov, R" uniqKey="Billeskov R">R Billeskov</name></author><author><name sortKey="Aagaard, C" uniqKey="Aagaard C">C Aagaard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Pinxteren, La" uniqKey="Van Pinxteren L">LA van Pinxteren</name></author><author><name sortKey="Cassidy, Jp" uniqKey="Cassidy J">JP Cassidy</name></author><author><name sortKey="Smedegaard, Bh" uniqKey="Smedegaard B">BH Smedegaard</name></author><author><name sortKey="Agger, Em" uniqKey="Agger E">EM Agger</name></author><author><name sortKey="Andersen, P" uniqKey="Andersen P">P Andersen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ordway, D" uniqKey="Ordway D">D Ordway</name></author><author><name sortKey="Higgins, Dm" uniqKey="Higgins D">DM Higgins</name></author><author><name sortKey="Sanchez Campillo, J" uniqKey="Sanchez Campillo J">J Sanchez-Campillo</name></author><author><name sortKey="Spencer, Js" uniqKey="Spencer J">JS Spencer</name></author><author><name sortKey="Henao Tamayo, M" uniqKey="Henao Tamayo M">M Henao-Tamayo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mogues, T" uniqKey="Mogues T">T Mogues</name></author><author><name sortKey="Goodrich, Me" uniqKey="Goodrich M">ME Goodrich</name></author><author><name sortKey="Ryan, L" uniqKey="Ryan L">L Ryan</name></author><author><name sortKey="Lacourse, R" uniqKey="Lacourse R">R LaCourse</name></author><author><name sortKey="North, Rj" uniqKey="North R">RJ North</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Cy" uniqKey="Chen C">CY Chen</name></author><author><name sortKey="Huang, D" uniqKey="Huang D">D Huang</name></author><author><name sortKey="Wang, Rc" uniqKey="Wang R">RC Wang</name></author><author><name sortKey="Shen, L" uniqKey="Shen L">L Shen</name></author><author><name sortKey="Zeng, G" uniqKey="Zeng G">G Zeng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Louise, R" uniqKey="Louise R">R Louise</name></author><author><name sortKey="Skjot, V" uniqKey="Skjot V">V Skjot</name></author><author><name sortKey="Agger, Em" uniqKey="Agger E">EM Agger</name></author><author><name sortKey="Andersen, P" uniqKey="Andersen P">P Andersen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reed, S" uniqKey="Reed S">S Reed</name></author><author><name sortKey="Lobet, Y" uniqKey="Lobet Y">Y Lobet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lewinsohn, Da" uniqKey="Lewinsohn D">DA Lewinsohn</name></author><author><name sortKey="Lines, Ra" uniqKey="Lines R">RA Lines</name></author><author><name sortKey="Lewinsohn, Dm" uniqKey="Lewinsohn D">DM Lewinsohn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schnappinger, D" uniqKey="Schnappinger D">D Schnappinger</name></author><author><name sortKey="Ehrt, S" uniqKey="Ehrt S">S Ehrt</name></author><author><name sortKey="Voskuil, Mi" uniqKey="Voskuil M">MI Voskuil</name></author><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y Liu</name></author><author><name sortKey="Mangan, Ja" uniqKey="Mangan J">JA Mangan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcdermott, Ab" uniqKey="Mcdermott A">AB McDermott</name></author><author><name sortKey="Koup, Ra" uniqKey="Koup R">RA Koup</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moss, P" uniqKey="Moss P">P Moss</name></author><author><name sortKey="Khan, N" uniqKey="Khan N">N Khan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Andersen, P" uniqKey="Andersen P">P Andersen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Horwitz, Ma" uniqKey="Horwitz M">MA Horwitz</name></author><author><name sortKey="Harth, G" uniqKey="Harth G">G Harth</name></author><author><name sortKey="Dillon, Bj" uniqKey="Dillon B">BJ Dillon</name></author><author><name sortKey="Maslesa Galic, S" uniqKey="Maslesa Galic S">S Maslesa-Galic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberts, Ad" uniqKey="Roberts A">AD Roberts</name></author><author><name sortKey="Sonnenberg, Mg" uniqKey="Sonnenberg M">MG Sonnenberg</name></author><author><name sortKey="Ordway, Dj" uniqKey="Ordway D">DJ Ordway</name></author><author><name sortKey="Furney, Sk" uniqKey="Furney S">SK Furney</name></author><author><name sortKey="Brennan, Pj" uniqKey="Brennan P">PJ Brennan</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Betts, Mr" uniqKey="Betts M">MR Betts</name></author><author><name sortKey="Ambrozak, Dr" uniqKey="Ambrozak D">DR Ambrozak</name></author><author><name sortKey="Douek, Dc" uniqKey="Douek D">DC Douek</name></author><author><name sortKey="Bonhoeffer, S" uniqKey="Bonhoeffer S">S Bonhoeffer</name></author><author><name sortKey="Brenchley, Jm" uniqKey="Brenchley J">JM Brenchley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lewinsohn, Dm" uniqKey="Lewinsohn D">DM Lewinsohn</name></author><author><name sortKey="Briden, Al" uniqKey="Briden A">AL Briden</name></author><author><name sortKey="Reed, Sg" uniqKey="Reed S">SG Reed</name></author><author><name sortKey="Grabstein, Kh" uniqKey="Grabstein K">KH Grabstein</name></author><author><name sortKey="Alderson, Mr" uniqKey="Alderson M">MR Alderson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heinzel, As" uniqKey="Heinzel A">AS Heinzel</name></author><author><name sortKey="Grotzke, Je" uniqKey="Grotzke J">JE Grotzke</name></author><author><name sortKey="Lines, Ra" uniqKey="Lines R">RA Lines</name></author><author><name sortKey="Lewinsohn, Da" uniqKey="Lewinsohn D">DA Lewinsohn</name></author><author><name sortKey="Mcnabb, Al" uniqKey="Mcnabb A">AL McNabb</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Riddell, Sr" uniqKey="Riddell S">SR Riddell</name></author><author><name sortKey="Watanabe, Ks" uniqKey="Watanabe K">KS Watanabe</name></author><author><name sortKey="Goodrich, Jm" uniqKey="Goodrich J">JM Goodrich</name></author><author><name sortKey="Li, Cr" uniqKey="Li C">CR Li</name></author><author><name sortKey="Agha, Me" uniqKey="Agha M">ME Agha</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Romani, N" uniqKey="Romani N">N Romani</name></author><author><name sortKey="Gruner, S" uniqKey="Gruner S">S Gruner</name></author><author><name sortKey="Brang, D" uniqKey="Brang D">D Brang</name></author><author><name sortKey="Kampgen, E" uniqKey="Kampgen E">E Kampgen</name></author><author><name sortKey="Lenz, A" uniqKey="Lenz A">A Lenz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brodie, Sj" uniqKey="Brodie S">SJ Brodie</name></author><author><name sortKey="Lewinsohn, Da" uniqKey="Lewinsohn D">DA Lewinsohn</name></author><author><name sortKey="Patterson, Bk" uniqKey="Patterson B">BK Patterson</name></author><author><name sortKey="Jiyamapa, D" uniqKey="Jiyamapa D">D Jiyamapa</name></author><author><name sortKey="Krieger, J" uniqKey="Krieger J">J Krieger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grotzke, Je" uniqKey="Grotzke J">JE Grotzke</name></author><author><name sortKey="Harriff, Mj" uniqKey="Harriff M">MJ Harriff</name></author><author><name sortKey="Siler, Ac" uniqKey="Siler A">AC Siler</name></author><author><name sortKey="Nolt, D" uniqKey="Nolt D">D Nolt</name></author><author><name sortKey="Delepine, J" uniqKey="Delepine J">J Delepine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gold, Mc" uniqKey="Gold M">MC Gold</name></author><author><name sortKey="Robinson, Tl" uniqKey="Robinson T">TL Robinson</name></author><author><name sortKey="Cook, Ms" uniqKey="Cook M">MS Cook</name></author><author><name sortKey="Byrd, Lk" uniqKey="Byrd L">LK Byrd</name></author><author><name sortKey="Ehlinger, Hd" uniqKey="Ehlinger H">HD Ehlinger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kiepiela, P" uniqKey="Kiepiela P">P Kiepiela</name></author><author><name sortKey="Leslie, Aj" uniqKey="Leslie A">AJ Leslie</name></author><author><name sortKey="Honeyborne, I" uniqKey="Honeyborne I">I Honeyborne</name></author><author><name sortKey="Ramduth, D" uniqKey="Ramduth D">D Ramduth</name></author><author><name sortKey="Thobakgale, C" uniqKey="Thobakgale C">C Thobakgale</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aagaard, C" uniqKey="Aagaard C">C Aagaard</name></author><author><name sortKey="Dietrich, J" uniqKey="Dietrich J">J Dietrich</name></author><author><name sortKey="Doherty, M" uniqKey="Doherty M">M Doherty</name></author><author><name sortKey="Andersen, P" uniqKey="Andersen P">P Andersen</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23805289</article-id><article-id pub-id-type="pmc">3689843</article-id><article-id pub-id-type="publisher-id">PONE-D-12-21473</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0067016</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group><subj-group><subject>Immunity</subject><subj-group><subject>Adaptive Immunity</subject><subject>Immunity to Infections</subject></subj-group></subj-group><subj-group><subject>Antigen Processing and Recognition</subject><subject>Immune Response</subject><subject>Major Histocompatibility Complex</subject></subj-group></subj-group><subj-group><subject>Microbiology</subject><subj-group><subject>Host-Pathogen Interaction</subject></subj-group></subj-group><subj-group><subject>Proteomics</subject><subj-group><subject>Peptide Mapping</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Bacterial Diseases</subject><subj-group><subject>Tuberculosis</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Human <italic>Mycobacterium tuberculosis</italic> CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide Library</article-title><alt-title alt-title-type="running-head">Peptide Library Defines Tuberculosis CD8 Antigens</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lewinsohn</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Swarbrick</surname><given-names>Gwendolyn M.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cansler</surname><given-names>Meghan E.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Null</surname><given-names>Megan D.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rajaraman</surname><given-names>Veena</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Frieder</surname><given-names>Marisa M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sherman</surname><given-names>David R.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>McWeeney</surname><given-names>Shannon</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lewinsohn</surname><given-names>Deborah A.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Division of Pulmonary and Critical Care Medicine, Oregon Health and Sciences University, Portland, Oregon</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Portland Veterans Administration Medical Center, Portland, Oregon</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Pediatrics, Oregon Health & Sciences University, Portland, Oregon</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Oregon Cancer Institute, Oregon Health & Sciences University, Portland, Oregon</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Seattle Biomedical Research Institute, Seattle, Washington</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Shams</surname><given-names>Homayoun</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1"><addr-line>Oregon Health and Science University, United States of America</addr-line></aff><author-notes><corresp id="cor1">* E-mail: <email>lewinsde@ohsu.edu</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>David M. Lewinsohn and Deborah A. Lewinsohn have the following conflicts and conflict resolution. DML and DAL are co-inventors on US patent 7,842,299 regarding use of Esx J, PE9, and PE_PGRS42 as CD8 antigens for TB diagnostics and vaccines. AERAS Foundation has licensed use of Esx J, PE9, and PE_PGRS42 for TB vaccine development from OHSU. DML and DAL receive royalty income for this license. Finally, DML and DAL hold financial interest in ViTi Corp and ViTi Corp has licensed use of Esx J, PE9, and PE_PGRS42 as CD8 antigens for TB diagnostic development. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. All others authors do not hold any conflict of interest as defined by PLoS ONE policy. Required public discloser language required by OHSU follows: Aeras TB Vaccine Foundation, a non-profit organization has licensed technology from OHSU of which David M. Lewinsohn and Deborah A. Lewinsohn are inventors. The technology is used in this research. This potential conflict has been reviewed and managed by OHSU. Furthermore, OHSU and David M. Lewinsohn and Deborah A. Lewinsohn have a financial interest in ViTi, a company that may have a commercial interest in the results of this research and technology. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: DML GMS DRS SM DAL. Performed the experiments: GMS MEC MDN VR. Analyzed the data: DML GMS VR SM DAL. Contributed reagents/materials/analysis tools: MMF DRS. Wrote the paper: DML GMS DAL.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>6</month><year>2013</year></pub-date><volume>8</volume><issue>6</issue><elocation-id>e67016</elocation-id><history><date date-type="received"><day>10</day><month>7</month><year>2012</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 Lewinsohn et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Lewinsohn et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>Identification of CD8<sup>+</sup> T cell antigens/epitopes expressed by human pathogens with large genomes is especially challenging, yet necessary for vaccine development. Immunity to tuberculosis, a leading cause of mortality worldwide, requires CD8<sup>+</sup> T cell immunity, yet the repertoire of CD8 antigens/epitopes remains undefined. We used integrated computational and proteomic approaches to screen 10% of the <italic>Mycobacterium tuberculosis</italic> (Mtb) proteome for CD8 Mtb antigens. We designed a weighting schema based upon a Multiple Attribute Decision Making:framework to select 10% of the Mtb proteome with a high probability of containing CD8<sup>+</sup> T cell epitopes. We created a synthetic peptide library consisting of 15-mers overlapping by 11 aa. Using the interferon-γ ELISPOT assay and Mtb-infected dendritic cells as antigen presenting cells, we screened Mtb-specific CD8<sup>+</sup> T cell clones restricted by classical MHC class I molecules (MHC class Ia molecules), that were isolated from Mtb-infected humans, against this library. Three novel CD8 antigens were unambiguously identified: the EsxJ family (Rv1038c, Rv1197, Rv3620c, Rv2347c, Rv1792), PE9 (Rv1088), and PE_PGRS42 (Rv2487c). The epitopes are B5701-restricted EsxJ<sub>24–34</sub>, B3905-restricted PE9<sub>53–67</sub>, and B3514-restricted PE_PGRS42<sub>48–56</sub>, respectively. The utility of peptide libraries in identifying unknown epitopes recognized by classically restricted CD8<sup>+</sup> T cells was confirmed, which can be applied to other intracellular pathogens with large size genomes. In addition, we identified three novel Mtb epitopes/antigens that may be evaluated for inclusion in vaccines and/or diagnostics for tuberculosis.</p></abstract><funding-group><funding-statement>This work was supported by a VA Merit Review Grant and the Portland VA Medical Center, US National Institutes of Health HHSN266200400081C (NO1-A1–400081), and R01AI48090. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"></page-count></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Effective vaccines for many important human pathogens have not yet been developed, and rational design of effective vaccines requires detailed knowledge of correlates of protective immunity. For intracellular pathogens which require T-cell mediated protection such as HIV, CMV, HSV, <italic>Mycobacterium tuberculosis</italic> (Mtb), <italic>Plasmodium</italic> species, <italic>Leishmania</italic> species, <italic>Chlamydiae</italic> species and <italic>Toxoplasma gondii</italic><xref rid="pone.0067016-Lewinsohn1" ref-type="bibr">[1]</xref>, definition of T cell antigens and epitopes is critical for the definition of these correlates. However, except perhaps for HIV <xref rid="pone.0067016-Day1" ref-type="bibr">[2]</xref>, we do not have a comprehensive understanding of human T cell antigens. This is due in part to the large genome size of many human pathogens making production and screening of peptide libraries prohibitively expensive and impractical to perform. Using Mtb as a model pathogen, we have developed an integrated computational and genomic screening approach to identify CD8 antigens.</p><p>Tuberculosis (TB), which is caused by infection with Mtb, represents one of the most important causes of morbidity and mortality worldwide, responsible for 9 million cases and 1.7 million deaths each year <xref rid="pone.0067016-1" ref-type="bibr">[3]</xref>. Although Bacille Calmette-Guerin (BCG) is the most widely administered vaccine in the world <xref rid="pone.0067016-2" ref-type="bibr">[4]</xref>, the incidence of TB has remained stable. Thus, elimination of TB worldwide will require a more effective vaccine, and this, in turn, will require a detailed knowledge of protective TB immunity.</p><p>Effective T cell responses are essential for TB immunity. Specifically, IFN-γ-producing CD4<sup>+</sup> Th1 cells have been shown to be critical for protection in the murine TB model <xref rid="pone.0067016-Flynn1" ref-type="bibr">[5]</xref> and depletion of CD4<sup>+</sup> T cells in AIDS patients renders them susceptible to TB <xref rid="pone.0067016-Barnes1" ref-type="bibr">[6]</xref>. Similar to viruses and some other intracellular bacteria such as Salmonella and Listeria <xref rid="pone.0067016-Oldstone1" ref-type="bibr">[7]</xref>, a protective role of CD8<sup>+</sup> T cell responses is supported by the murine TB model <xref rid="pone.0067016-Woodworth1" ref-type="bibr">[8]</xref> and Mtb-specific CD8<sup>+</sup> T cells are found in Mtb-infected humans and include both T cells classically restricted by HLA-Ia <xref rid="pone.0067016-Lalvani1" ref-type="bibr">[9]</xref>–<xref rid="pone.0067016-Cho1" ref-type="bibr">[12]</xref> and non-classically restricted by HLA-E <xref rid="pone.0067016-Grotzke1" ref-type="bibr">[13]</xref> and MR1 <xref rid="pone.0067016-Gold1" ref-type="bibr">[14]</xref>. While CD8<sup>+</sup> T cells have redundant function with CD4<sup>+</sup> T cells, such as activating infected macrophages with IFN-γ, as well as the use of the granule exocytosis pathway <xref rid="pone.0067016-Lewinsohn4" ref-type="bibr">[15]</xref>, CD8<sup>+</sup> T cells also have the potential to play a unique role in the recognition and containment of intracellular infection with Mtb. For example, CD8<sup>+</sup> T cells can lyse infected MHC Class II negative cells such as lung epithelial cells <xref rid="pone.0067016-Gold1" ref-type="bibr">[14]</xref>. Furthermore, CD8<sup>+</sup> T cells preferentially recognize and eliminate heavily infected cells <xref rid="pone.0067016-Lewinsohn5" ref-type="bibr">[16]</xref>. Thus, CD8<sup>+</sup> T cells may provide a secondary line of defense when CD4<sup>+</sup> T cell-activated macrophages fail to contain infection. Furthermore, in the setting of persistent infection with Mtb, CD8<sup>+</sup> T cells may play a vital role in the immune-surveillance and containment of intracellular infection. The importance of CD8<sup>+</sup> T cells in the persistent phase of Mtb infection has been highlighted by studies utilizing the mouse <xref rid="pone.0067016-Hoang1" ref-type="bibr">[17]</xref>–<xref rid="pone.0067016-Mogues1" ref-type="bibr">[20]</xref> and non-human primate <xref rid="pone.0067016-Chen1" ref-type="bibr">[21]</xref> TB models. As a result, vaccines capable of eliciting CD8<sup>+</sup> T cell responses represent an important goal for vaccine-induced protection from TB.</p><p>While CD4 antigens have been extensively characterized <xref rid="pone.0067016-Louise1" ref-type="bibr">[22]</xref>, <xref rid="pone.0067016-Reed1" ref-type="bibr">[23]</xref>, the antigens/epitopes recognized by Mtb-specific CD8<sup>+</sup> T cells remain poorly defined. Previously, most CD8 epitopes had been identified by testing of Mtb peptides selected for high-affinity binding to classical MHC class I molecules (MHC class Ia molecules), mainly HLA-A2 (reviewed in <xref rid="pone.0067016-Grotzke1" ref-type="bibr">[13]</xref>). However, the majority of these epitopes are not strongly recognized by Mtb-infected individuals. In contrast, cases where T cells isolated from Mtb-infected individuals have been used to define epitopes, strongly and commonly recognized epitopes have been identified <xref rid="pone.0067016-Lewinsohn2" ref-type="bibr">[10]</xref>, <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>, <xref rid="pone.0067016-Lewinsohn6" ref-type="bibr">[24]</xref>. In this regard, we have isolated CD8<sup>+</sup> T cell clones that recognize Mtb-infected dendritic cells (DC) from Mtb-infected individuals and used these T cell clones as a powerful tool to identify novel strongly and commonly recognized CD8 epitopes contained within known CD4 antigens represented by synthetic peptide pools <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>. This was a successful approach in that about two thirds of MHC Ia-restricted Mtb-specific CD8<sup>+</sup> T cell clones isolated in our laboratory recognize epitopes contained within CD4 antigens. Herein, we screen the CD8<sup>+</sup> T cell clones for which no antigen was identified by screening against the limited peptide library representing known CD4 antigens, against a synthetic overlapping peptide pool library representing approximately 10% of the Mtb proteome likely to contain CD8 antigens. Using this approach we define three previously unknown CD8 antigens and epitopes processed and presented by Mtb-infected DC and recognized by individuals with latent tuberculosis infection (LTBI) or TB.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Design and synthesis of synthetic peptide library</title><p>Initially, a comprehensive evaluation of available genomic and proteomic information was performed. For genomic information, published information was evaluated with regard to its integrity and internal consistency. We first compiled genomic (TubercuList, <ext-link ext-link-type="uri" xlink:href="http://genolist.pasteur.fr/TubercuList/">http://genolist.pasteur.fr/TubercuList/</ext-link> and <xref rid="pone.0067016-Schnappinger1" ref-type="bibr">[25]</xref>) and proteomic (<ext-link ext-link-type="uri" xlink:href="http://web.mpiib-berlin.mpg.de/cgi-bin/pdbs/2d-page/extern/index.cgi">http://web.mpiib-berlin.mpg.de/cgi-bin/pdbs/2d-page/extern/index.cgi</ext-link> and Dr. Karen Dobos, Colorado State University, personal communication) Mtb expression data and meta-data from published sources, from publicly available sources, or available to us as a personal communication. We then loaded these data into an Oracle 9i database.</p><p>We designed a weighting schema based upon a Multiple Attribute Decision Making (MADM):framework. First, to calculate the TubercuList Functional Score, each gene was evaluated for weighting based upon functional attributes reflected in TubercuList (<xref ref-type="table" rid="pone-0067016-t001">Table 1</xref>). Functional categories including “PPE/PE”, “cell wall and cell processes”, “virulence, detoxification, adaptation” were given a greater weighting than functional categories such as “intermediary metabolism” due to their potentially greater significance in the immune response to Mtb. For example, cell wall and associated proteins were prioritized because structural components of intracellular pathogens are the first proteins processed and presented to the immune system and often represent CD8 antigens, such as the HIV gag proteins <xref rid="pone.0067016-McDermott1" ref-type="bibr">[26]</xref>, <xref rid="pone.0067016-Moss1" ref-type="bibr">[27]</xref>. Finally, because CD4 antigens are preferentially expressed as secreted proteins <xref rid="pone.0067016-Reed1" ref-type="bibr">[23]</xref>, <xref rid="pone.0067016-Andersen1" ref-type="bibr">[28]</xref>–<xref rid="pone.0067016-Lambert1" ref-type="bibr">[31]</xref> and CD4 antigens are often CD8 antigens <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>, genes where the word “secreted” was found in the text description were weighted as well. The TubercuList Functional Score was calculated as the total score based on TubercuList attributes. For example a gene classified as a PE/PPE family member (score = 10) and as in the cell wall (score = 8) would be assigned a TubercuList Functional Score = 18. Gene products with a TubercuList Functional Score ≥10 were included in the library. Additionally, gene products where the word “secreted” was identified in the text description, but which nonetheless had a TubercuList Functional Score <10, were also included in the library.</p><table-wrap id="pone-0067016-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0067016.t001</object-id><label>Table 1</label><caption><title>TubercuList Functional Score.</title></caption><alternatives><graphic id="pone-0067016-t001-1" xlink:href="pone.0067016.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">PE/PPE</td><td align="left" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">Cell wall and cell processes</td><td align="left" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">Virulence, detoxification, adaptation</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Lipid metabolism</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Conserved Hypotheticals</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Regulatory proteins</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">All other</td><td align="left" rowspan="1" colspan="1">−10</td></tr><tr><td align="left" rowspan="1" colspan="1">“Secreted”</td><td align="left" rowspan="1" colspan="1">10</td></tr></tbody></table></alternatives></table-wrap><p>Second, a Composite Evidence Score was calculated. This score included additional components of weighting such that each gene was assigned weight based upon three additional lines of evidence (<xref ref-type="table" rid="pone-0067016-t002">Table 2</xref>). These were: 1) Proteomic data: These data included cell-associated proteins from the Erdmann strain, secreted and cell-associated proteins from H37Rv Mtb (<ext-link ext-link-type="uri" xlink:href="http://web.mpiib-berlin.mpg.de/cgi-bin/pdbs/2d-page/extern/index.cgi">http://web.mpiib-berlin.mpg.de/cgi-bin/pdbs/2d-page/extern/index.cgi</ext-link>), and additional data on cell-associated and secreted proteins from the H37Rv strain (Dr. Karen Dobos, Colorado State University, personal communication). As with the TubercuList Functional Score, proteins detected as secreted proteins (supernatant fractions) were given a greater weighting (secreted = 7) than cell-associated gene products (cell pellet fractions or cell pellet and secreted fractions = 4). 2) Genomic data: Transcriptional profiling of Mtb gene expression in macrophages <xref rid="pone.0067016-Schnappinger1" ref-type="bibr">[25]</xref> was weighted based on constitutive or induced expression. Specifically, gene products with evidence for differential expression associated with adaptation to intracellular growth or stress such that they were induced in one or more experimental condition (1–11 of 12 conditions = 8) were given greater weighting than genes which were constitutively expressed (12 of 12 conditions = 6). 3) Not in Bacille Calmeette-Guerin (BCG): Genes not expressed in BCG were assigned a positive weight (score = 10, Behr: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10348738">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10348738</ext-link>). To obtain the Composite Evidence Score, the TubercuList Functional Score was added only to additional components scores with non-zero values, and then all three scores were averaged. For example, for Rv3874 (<xref ref-type="supplementary-material" rid="pone.0067016.s001">Table S1</xref>) Score = 10, the Composite Evidence Based Score would be (4+8) +0+ (10+8)/3 = 10. Gene products with a Composite Evidence Score ≥5.33 were included in the library.</p><table-wrap id="pone-0067016-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0067016.t002</object-id><label>Table 2</label><caption><title>Additional components of Composite Evidence Score.</title></caption><alternatives><graphic id="pone-0067016-t002-2" xlink:href="pone.0067016.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">Proteomic</td><td align="left" rowspan="1" colspan="1">Cellular</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Secreted</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Both</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Genomic</td><td align="left" rowspan="1" colspan="1">12/12 Conditions</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1–11 Conditions</td><td align="left" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">Not in BCG</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">10</td></tr></tbody></table></alternatives></table-wrap><p>The synthetic peptide library representing the selected 10% of the Mtb proteome was provided by Jerini Peptide Technologies. The peptide library was comprised of 15-mers overlapping by 11 a.a. (final concentration of individual peptides, 50 nmol) comprising 50 peptide pools in a 96 well format. Construction of the library with 15-mers overlapping by 11 a.a's allowed ex vivo CD8<sup>+</sup> T cells to be readily detected and ensured that all possible candidate epitopes are represented by at least one 15-mer <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>, <xref rid="pone.0067016-Betts1" ref-type="bibr">[32]</xref>. Five blank wells and one well of an irrelevant peptide pool representing SIV Gag, were included on each of the nine plates. Peptide pools libraries were stored at −80°C.</p></sec><sec id="s2a1"><title>Study participants</title><p>Study participants, protocols, and consent forms were approved by the Oregon Health & Science University institutional review board. Written informed consent was obtained from all participants. Individuals with LTBI and uninfected individuals were recruited from employees at Oregon Health &Science University and the general public and active TB donors were recruited from the Multnomah Tuberculosis Clinic, Portland, OR, as previously described <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>. Uninfected individuals were defined as healthy individuals with a history of a negative self-reported tuberculin skin test and no known risk factors for Mtb infection. LTBI was defined as a self-reported history of a tuberculin skin test in a healthy person. Active TB was defined by a person with a recent history of pulmonary TB confirmed by a positive sputum culture. PBMCs were isolated from whole blood obtained by venipuncture or apheresis.</p></sec><sec id="s2b"><title>Media and reagents</title><p>For the growth and assay of Mtb-reactive T cell clones, RPMI 1640 supplemented with 10% human sera, gentamicin (50 µg/ml), and 2 mM glutamine (GIBCO BRL, <ext-link ext-link-type="uri" xlink:href="http://www.invitrogen.com/">http://www.invitrogen.com/</ext-link>) was used. Mtb strain H37Rv was obtained from the American Type Culture Collection (<ext-link ext-link-type="uri" xlink:href="http://www.atcc.org/">http://www.atcc.org/</ext-link>) and prepared as previously described <xref rid="pone.0067016-Lewinsohn7" ref-type="bibr">[33]</xref>.</p></sec><sec id="s2c"><title>Cell lines and T cell clones</title><p>EBV-transformed B cell lines, lymphoblastoid cell lines (LCL), were either generated in our laboratory using supernatants from the cell line 9B5–8 (American Type Culture Collection) or obtained from the National Marrow Donor Program (<ext-link ext-link-type="uri" xlink:href="http://www.marrow.org/">http://www.marrow.org/</ext-link>). LCL were maintained by continuous passage as previously described <xref rid="pone.0067016-Heinzel1" ref-type="bibr">[34]</xref>. Mtb-specific T cell clones were isolated from individuals with LTBI or history of active TB, using Mtb-infected DCs as APC and limiting dilution cloning methodology as previously described <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>, <xref rid="pone.0067016-Lewinsohn7" ref-type="bibr">[33]</xref>. Isolated T cell clones specifically recognizing Mtb-specific DC versus uninfected DC by IFN-γ ELISPOT assay, were further characterized. Confirmation of CD8 expression, αβ TCR expression, and determination of the TCR Vβ chain (IOTest Beta Mark Kit, [Beckman Coulter]) were performed by flow cytometry, and determination of HLA-Ia allele restriction was performed by determination of discriminative recognition of single HLA-Ia allele mismatched APC target cells. While our focus was on antigens/epitopes recognized by classically restricted, HLA-Ia-restricted T cell clones, experiments included non-classically restricted, HLA-Ib-restricted T cell clones defined as T cell clones that recognized Mtb-infected autologous DC, Mtb-infected HLA-Ia mismatched DC, and Mtb-infected HLA-Ia mismatched macrophages, but not uninfected autologous DC. For all experiments, T cell clones were expanded using anti-CD3 mAb stimulation as previously described <xref rid="pone.0067016-Heinzel1" ref-type="bibr">[34]</xref>, <xref rid="pone.0067016-Riddell1" ref-type="bibr">[35]</xref>.</p></sec><sec id="s2d"><title>Generation and infection of peripheral blood DC</title><p>Monocyte-derived DC were prepared according to a modified method of Romani et al. <xref rid="pone.0067016-Heinzel1" ref-type="bibr">[34]</xref>, <xref rid="pone.0067016-Romani1" ref-type="bibr">[36]</xref>. To generate Mtb-infected DC, day 5 DC (1×10<sup>6</sup>/well) were cultured overnight in the presence of Mtb at a multiplicity of infection = 30∶1. As heavy infection is required to optimize entry of antigen into the class I processing pathway <xref rid="pone.0067016-Lewinsohn5" ref-type="bibr">[16]</xref>, we have determined that this multiplicity of infection is optimal for detection of Mtb-specific CD8<sup>+</sup> T cells. After 18 h, the cells were harvested and resuspended in RPMI/10% human serum.</p></sec><sec id="s2e"><title>Screen of peptide library using IFN-γ ELISPOT assay</title><p>The IFN-γ ELISPOT assay was performed as described previously <xref rid="pone.0067016-Heinzel1" ref-type="bibr">[34]</xref>. To test the T cell clones against Mtb-infected DC, T cell clones (5000 cells/well) were cultured with autologous DC (20,000 cells/well), which were either uninfected or infected with Mtb, overnight in the IFN-γ ELISPOT assay. For the screen, T cell clones (5,000 cells/well of each clone), autologous DC (20,000 cells/well), IL-2 (0.5 ng/ml) and the peptide pools (5 µg/ml, individual peptides) were tested in the IFN-γ ELISPOT assay using one technical replicate. Negative and positive controls consisted of wells containing T cells and DC either without antigen or without antigen but with inclusion of PHA (10 µg/ml; Sigma Aldrich, <ext-link ext-link-type="uri" xlink:href="http://www.sigmaaldrich.com/">http://www.sigmaaldrich.com/</ext-link>), respectively. For all assays, responding T cells were incubated with APCs overnight.</p></sec><sec id="s2f"><title>IFN-γ ELISPOT analysis for fine epitope mapping and HLA-I restricting allele determination</title><p>Determination of the minimal epitope recognized and of the HLA-I allele restricting each of the epitopes was performed exactly as described previously <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>. Briefly, to determine the minimal epitope recognized, first the T cell clone (5000 cells/well) was incubated with autologous LCL (20,000 cells/well) in the presence of individual 15-mer peptides (5 µg/ml) as the source of antigen in an IFN-γ ELISPOT assay. Then having identified the unique 15-mer recognized, the IFN-γ ELISPOT assay was repeated using the individual nested peptides (including 8-, 9-, 10-, 11-, and/or 12-mer peptides, 5 g/ml) as a source of antigen. To determine the minimal epitope, T cell clones (1000 cells/well) were incubated with autologous LCL (20,000 cells/well) with the individual nested peptides recognized by the T cell clone over a range of concentrations. By definition, the minimal epitope is the peptide eliciting a T cell response at the lowest concentration. To determine the restricting allele, T cell clones (500 cells/well) were incubated with LCL (20,000 cells/well) that were autologous or expressed HLA alleles matching at only one allele in the presence of peptide representing the epitope (5 µg/ml). A negative control (media, no peptide) and a positive control (PHA, 10 µg/ml) were included in each assay. The restricting allele of each T cell clone was determined by testing against peptide-pulsed LCL sharing at least one HLA allele with the donor.</p></sec><sec id="s2g"><title>Determination of ex vivo T cell frequencies</title><p>The ex vivo T cell frequency was also determined as described previously <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>. Briefly, CD8<sup>+</sup> T cells were selected from PBMCs using magnetic beads resulting in a>97% pure population. Using this CD8 selected population as a source of responding T cells, T cells (5X10<sup>5</sup>, 2.5X10<sup>5</sup>, 1.2X10<sup>5</sup>, and 6X10<sup>4</sup> cells/well) were incubated with autologous DC (20,000 cells/well) pulsed with the peptide representing the minimal epitope (5 µg/ml) in an IFN-γ ELISPOT assay.</p></sec><sec id="s2h"><title>Data analysis</title><p>To determine the ex vivo T cell frequencies, linear regression analysis was used as described previously <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Creation of peptide library</title><p>We utilized integrated computational and proteomic approaches to select 389 genes from the Mtb genome (4011 genes), to comprise the peptide library (<xref ref-type="supplementary-material" rid="pone.0067016.s001">Table S1</xref>). First, we chose 34 genes of special interest which were comprised of: 1) gene products shown previously in our laboratory to be recognized by CD8<sup>+</sup> T cells from Mtb-infected individuals (<italic>n</italic> = 10); 2) gene products determined previously to represent CD4 antigens ((22, 23), <italic>n</italic> = 9); and 3) genes that were annotated as “ESAT-like” in Tuberculist (<italic>n</italic> = 15). Next, we selected 256 genes with a Tuberculist Functional Score (assigned as described in <xref ref-type="sec" rid="s2">Methods</xref>) ≥10 and then selected 91 genes with a Composite Evidence-Based Score (assigned as described in <xref ref-type="sec" rid="s2">Methods</xref>) ≥5.33. Finally, we selected genes that were categorized as “secreted” in TubercuList but nonetheless did not have a TubercuList Functional Score ≥10 (<italic>n</italic> = 8) for a total of 389 genes. Secreted proteins were selected based on the observation that secreted proteins from Mtb were often associated with vaccine efficacy <xref rid="pone.0067016-Reed1" ref-type="bibr">[23]</xref>, <xref rid="pone.0067016-Andersen1" ref-type="bibr">[28]</xref>–<xref rid="pone.0067016-Lambert1" ref-type="bibr">[31]</xref>. The thresholds of 5.33 and 10 were chosen to yield a number of remaining genes to attain a total less than 400 genes of interest. The numbers of genes from each Tuberculist functional category are shown in <xref ref-type="table" rid="pone-0067016-t003">Table 3</xref>. Utilizing the finalized gene list, 39,499 peptides were synthesized by Jerini Peptide Technologies to represent the proteins encoded by the 389 selected genes. Each peptide (50 nmol) was synthesized individually and then pooled into 789 pools (50 peptides/pool) in a 96 well format in a total of nine plates.</p><table-wrap id="pone-0067016-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0067016.t003</object-id><label>Table 3</label><caption><title>Number of genes according to functional category.</title></caption><alternatives><graphic id="pone-0067016-t003-3" xlink:href="pone.0067016.t003"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Functional Category<xref ref-type="table-fn" rid="nt101">1</xref></td><td align="left" rowspan="1" colspan="1">Number of genes</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PE/PPE</td><td align="left" rowspan="1" colspan="1">168</td></tr><tr><td align="left" rowspan="1" colspan="1">Cell wall and cell processes</td><td align="left" rowspan="1" colspan="1">134</td></tr><tr><td align="left" rowspan="1" colspan="1">Conserved hypotheticals</td><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">Virulence, detoxification, adaptation</td><td align="left" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1">Intermediary metabolism and respiration</td><td align="left" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">Lipid metabolism</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">Regulatory proteins</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Conserved hypotheticals with an orthologue in <italic>M. bovis</italic></td><td align="left" rowspan="1" colspan="1">4</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>1</label><p>Functional categories assigned by TubercuList.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Proof of principle CFP-10</title><p>Before screening the T cell clones against the genomic peptide library, the clones were first expanded and tested against Mtb-infected DC to ensure that each clone from this particular expansion yielded a robust Mtb-specific signal in the IFN-γ ELISPOT assay. The expansion of the T cell clone was considered acceptable for use in the peptide library screen if the response of the T cell clone to uninfected DC was <10 spot forming units (SFU)/well and to Mtb-infected DC was >50 SFU/well. To conserve on the use of the genomic peptide library, up to six different T cell clones were pooled and screened in an IFN-γ ELISPOT in the presence of the peptide pools, autologous DC and IL-2. Only one technical replicate was done per pool because, in our experience, 5000 T cell clones per well with a peptide antigen will produce an overwhelmingly positive response, resulting in a clear yes/no answer, while conserving the use of the peptide library. Negative and positive controls were included as described in the methods. As a proof of principle, a CFP-10-specific classically Ia-restricted CD8<sup>+</sup> T cell clone, D432 A5, was included in the first library screen with 4 classically restricted (D432 D2, D432 E7, D432 E8, D432 H8) and 1 non-classically restricted T cell clone (D432 B12) with unknown antigen specificity. T cells responded to plate 4 of 9, well A11, which contained 22 overlapping peptides representing CFP-10, as well as 9 peptides partially representing Rv3877, and 18 peptides partially representing 19 kd (<xref ref-type="fig" rid="pone-0067016-g001">Figure 1A</xref>). T cell clones were then tested against the individual peptides comprising this peptide pool. As expected, D432 A5 recognized two distinct 15-mers CFP-10<sub>45–59</sub> and CFP-10<sub>49–63</sub>, both of which contain the minimal epitope, CFP-10<sub>49–58</sub> (<xref ref-type="fig" rid="pone-0067016-g001">Figure 1b</xref>).</p><fig id="pone-0067016-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0067016.g001</object-id><label>Figure 1</label><caption><title>Screen of CFP10-specific CD8<sup>+</sup> T cell clone, D432 A5, against peptide library.</title><p>A) D432 A5, D432 D2, D432 E7, D432 E8, D432 H8 and D432 A11 T cells (5000 cells of each clone/well) were incubated with DC (20,000 cells/well) in the presence of the peptide pools (5 µg/ml, individual peptides) and IL-2 (0.5 ng/ml) in single wells in the IFN-γ ELISPOT assay. Positive well is plate 4 well A11. B) To identify the epitope recognized by T cell clone, D432 A5, T cells (5,000 cells/well) were incubated in single wells with autologous LCL (20,000 cells/well) and individual 15 aa peptides from Rv0377, Rv3763 and CFP10 (5 µg/ml) that together constitute the peptide pool from Plate 4 well A11. IFN-γ was assessed by ELISPOT after 18 hours of co-culture. Pictures of ELISPOT wells are shown.</p></caption><graphic xlink:href="pone.0067016.g001"></graphic></fig></sec><sec id="s3c"><title>Summary of T cell clone screening results</title><p>Classically restricted CD8<sup>+</sup> T cell clones isolated from ten donors (LTBI, <italic>n</italic> = 4; active TB, <italic>n</italic> = 6) had been previously screened against peptide pools representing known CD4 antigens which represented the following proteins: 1) Esat-6, Rv3875; 2) CFP-10, Rv3874; 3) Ag85B, Rv1886c; 4) Mtb9.8, EsxG, Rv0287; 5) 19 kd lipoprotein, Rv3763; 6) TB8.4,Mtb8.4, Rv1174c; 7) Mtb39a, Rv1196; and 8) Mtb9.9, family of ESAT-6 like proteins comprised of EsxN, Rv1793; EsxO, Rv2346c; EsxI, Rv1037c; EsxV, Rv3619c; and EsxL, Rv1198. T cell clones that recognized one of these eight antigens had minimal epitopes mapped as described previously <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>. Mtb-specific, classically restricted T cell clones that did not recognize any of these eight antigens (<italic>n</italic> = 14) isolated from donors with LTBI (D504) or active TB (D432, D466), as well as non-classically restricted T cell clones from these same donors (<italic>n</italic> = 33) were screened against the peptide library. The epitope recognized by 9 of the 14 classically restricted T cell clones was defined. These included 3 of 7 T cell clones isolated from D432, which recognized three distinct epitopes, and all 6 of 6 T cell clones isolated from D504, which all recognized one epitope. Three of four epitopes represent novel epitopes that have not been previously defined. The antigen/epitope recognized by the single T cell clone from D466 was not identified using the peptide library, nor were any of the antigens recognized by non-classically restricted T cell clones.</p></sec><sec id="s3d"><title>Example of epitope identification: T cell clones recognizing EsxJ</title><p>In one experiment, five T cell clones from D504, including four classically-restricted T cell clones (D504 B6, D504 B10, D504 F9 and D504 H6) and one non-classically restricted T cell clone (D504 A11), were screened against the peptide library. T cells recognized five distinct wells (four wells on plate 3 and one well on plate 4). Each well of the peptide library contained 50 peptides, which represent one to three genes. All gene products represented by peptides in these five wells belong to the Tuberculist category, “Cell wall and cell processes”. For each of the positive wells of this screen, the peptides contained in these wells and the corresponding gene products are summarized in <xref ref-type="table" rid="pone-0067016-t004">Table 4</xref>. EsxI and EsxO are part of the Mtb9.9 family of genes. As each clone had been previously screened against and did not recognize a peptide pool representing this antigen family, these Mtb9.9 proteins (EsxI and EsxO) were not considered further as candidate antigens. The EsxJ family share 98% homology with each other and differ from one another at only three amino acids (<xref ref-type="table" rid="pone-0067016-t005">Table 5</xref>). As four of the five positive wells from the screen contain peptides from one of four EsxJ family members, we predicted that at least one of the T cell clones screened recognized a single epitope represented in all four wells. We also predicted that this epitope would be located at the carboxyl terminus of the EsxJ, as well F10, plate 3 contained only 9 peptides representing the carboxyl terminus of EsxP<sub>1–43</sub>.</p><table-wrap id="pone-0067016-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0067016.t004</object-id><label>Table 4</label><caption><title>Description of peptides comprising positive wells.</title></caption><alternatives><graphic id="pone-0067016-t004-4" xlink:href="pone.0067016.t004"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Plate</td><td align="left" rowspan="1" colspan="1">Well</td><td align="left" rowspan="1" colspan="1">Rv</td><td align="left" rowspan="1" colspan="1">Name</td><td align="left" rowspan="1" colspan="1"># Peptides in Pool</td><td align="left" rowspan="1" colspan="1"># Peptides in Protein</td><td align="left" rowspan="1" colspan="1">Description from Tuberculist</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">A12</td><td align="left" rowspan="1" colspan="1">Rv1037c</td><td align="left" rowspan="1" colspan="1">EsxI<xref ref-type="table-fn" rid="nt102">1</xref></td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">Putative Esat-6 like protein EsxI (Esat-6 like protein 1)</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">A12</td><td align="left" rowspan="1" colspan="1">Rv1038c</td><td align="left" rowspan="1" colspan="1">EsxJ<xref ref-type="table-fn" rid="nt103">2</xref></td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">Esat-6 like protein EsxJ (Esat-6 like protein 2)</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">A12</td><td align="left" rowspan="1" colspan="1">Rv1072</td><td align="left" rowspan="1" colspan="1">Rv1072</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">Probably conserved transmembrane protein</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">B6</td><td align="left" rowspan="1" colspan="1">Rv1184c</td><td align="left" rowspan="1" colspan="1">Rv1184c</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">Possible exported protein</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">B6</td><td align="left" rowspan="1" colspan="1">Rv1197</td><td align="left" rowspan="1" colspan="1">EsxK<xref ref-type="table-fn" rid="nt103">2</xref></td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">Esat-6 like protein EsxK (Esat-6 like protein 3)</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">B6</td><td align="left" rowspan="1" colspan="1">Rv1198</td><td align="left" rowspan="1" colspan="1">EsxL<xref ref-type="table-fn" rid="nt102">1</xref></td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">Esat-6 like protein EsxL (Esat-6 like protein 4</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">F10</td><td align="left" rowspan="1" colspan="1">Rv2330c</td><td align="left" rowspan="1" colspan="1">LppP</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">Probably lipoprotein LPPP</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">F10</td><td align="left" rowspan="1" colspan="1">Rv2346c</td><td align="left" rowspan="1" colspan="1">EsxO<xref ref-type="table-fn" rid="nt102">1</xref></td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">Putative Esat-6 like protein EsxO (Esat-6 like protein 6)</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">F10</td><td align="left" rowspan="1" colspan="1">Rv2347c</td><td align="left" rowspan="1" colspan="1">EsxP<xref ref-type="table-fn" rid="nt103">2</xref></td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">Putative Esat-6 like protein EsxP (Esat-6 like protein 7)</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">G7</td><td align="left" rowspan="1" colspan="1">Rv2686c</td><td align="left" rowspan="1" colspan="1">Rv2686c</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">Probably antibiotic-transport integral leucine and alanine and valine rich protein ABC transporter</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">G7</td><td align="left" rowspan="1" colspan="1">Rv2687c</td><td align="left" rowspan="1" colspan="1">Rv2687c</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">Probably antibiotic-transport integral leucine and valine rich protein ABC transporter</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">A8</td><td align="left" rowspan="1" colspan="1">Rv3620c</td><td align="left" rowspan="1" colspan="1">EsxW<xref ref-type="table-fn" rid="nt103">2</xref></td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">Putative Esat-6 like protein EsxW (Esat-6 like protein 10)</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">A8</td><td align="left" rowspan="1" colspan="1">Rv3641c</td><td align="left" rowspan="1" colspan="1">Fic</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">Possible cell filamentation protein FIC</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label>1</label><p>Member of Mtb 9.9 gene family.</p></fn><fn id="nt103"><label>2</label><p>Member of EsxJ gene family.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0067016-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0067016.t005</object-id><label>Table 5</label><caption><title>Esx J family members.</title></caption><alternatives><graphic id="pone-0067016-t005-5" xlink:href="pone.0067016.t005"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">EsxJ</td><td align="left" rowspan="1" colspan="1">MASRFMTDPHAMRDMAGRFEVHAQTVEDEARRMWASAQNISGAGWSGMAEATSLD</td></tr><tr><td align="left" rowspan="1" colspan="1">EsxW</td><td align="left" rowspan="1" colspan="1">- TS - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -</td></tr><tr><td align="left" rowspan="1" colspan="1">EsxK</td><td align="left" rowspan="1" colspan="1">- AS - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -</td></tr><tr><td align="left" rowspan="1" colspan="1">EsxP</td><td align="left" rowspan="1" colspan="1">- AT - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -</td></tr><tr><td align="left" rowspan="1" colspan="1">EsxJ</td><td align="left" rowspan="1" colspan="1">TMTQMNQAFRNIVNMLHGVRDGLVRDANNYEQQEQASQQILSS</td></tr><tr><td align="left" rowspan="1" colspan="1">EsxW</td><td align="left" rowspan="1" colspan="1">-- --T- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -</td></tr><tr><td align="left" rowspan="1" colspan="1">EsxK</td><td align="left" rowspan="1" colspan="1">-- --A- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -</td></tr><tr><td align="left" rowspan="1" colspan="1">EsxP</td><td align="left" rowspan="1" colspan="1">-- --A- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -</td></tr></tbody></table></alternatives></table-wrap><p>We next screened each of the T cell clones individually against individual 15-mers representing the EsxJ family, including multiple peptides representing divergent sequences of the family members. Each T cell clone was also screened against individual peptides (<italic>n</italic> = 50) contained in well G7, plate 3, representing gene products of most of Rv2686c and part of Rv2687c. All four classically-restricted T cell clones recognized only one 15-mer, EsxJ<sub>21–35</sub> which represents a conserved region of the EsxJ family and which was present in all four wells containing peptides representing EsxJ family members. Next, the individual T cell clones were screened against all possible 9-, 10-, and 11-mers contained within EsxJ<sub>21–35</sub>. As shown for one representative clone, D504 F9, (<xref ref-type="fig" rid="pone-0067016-g002">Figure 2A</xref>), all four T cell clones recognizing EsxJ<sub>21–35</sub> also recognized peptide EsxJ<sub>24–34</sub> at the lowest concentration compared to the other peptides tested, defining EsxJ<sub>24–34</sub> as the minimal epitope.</p><fig id="pone-0067016-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0067016.g002</object-id><label>Figure 2</label><caption><title>Epitope mapping of EsxJ-specific CD8<sup>+</sup> T cell clones.</title><p>To map the minimal epitopes of CD8<sup>+</sup> T cell clones, A) D504 F9, B) 432 D8, and C) D432 H8, autologous LCL (20,000 cells/well) were pulsed with peptide at the concentrations indicated and co-cultured with T cells (1000 cells/well) in duplicate wells. IFN-γ was assessed by ELISPOT after 18 h co-culture. Each point represents the mean of duplicate determinations.</p></caption><graphic xlink:href="pone.0067016.g002"></graphic></fig></sec><sec id="s3e"><title>Summary of characterization of T cell clones</title><p>In a separate experiment, an additional two T cell clones from D504, D504 D2 and D504 D12, (total, <italic>n</italic> = 6) were screened against the peptide library and also recognized minimal epitope EsxJ<sub>24–34</sub>. The peptide library screen of one T cell clone from donor D466, D466 C7, was negative. Finally, seven T cell clones from D432 were screened. D432 A5 recognizes CFP-10<sub>49–58</sub> as shown above. D432 D8 recognized a well containing peptides representing PE9. Within PE9, this clone recognized a single 15-mer, PE9<sub>53–67</sub>. D432 D8 was then screened against all possible 9-, 10-, and 11-mers contained in PE9<sub>53–67</sub>, but no nested peptide was recognized at a lower concentration than PE9<sub>53–67</sub> (<xref ref-type="fig" rid="pone-0067016-g002">Figure 2B</xref>). Thus, we were unable to define the minimal epitope recognized by D432 D8 within PE9<sub>53–57</sub>. Finally D432 H8 recognized a well containing peptides representing PE_PGRS42 and a single 15-mer, PE_PGS42<sub>41–55</sub>. D432 H8 recognized PE_PGS42<sub>48–56</sub> at the lowest concentration compared to the other peptides tested, defining PE_PGS42<sub>48–56</sub> as the minimal epitope (<xref ref-type="fig" rid="pone-0067016-g002">Figure 2C</xref>).</p><p>Further characterization of the three T cell clones recognizing novel epitopes is summarized in <xref ref-type="table" rid="pone-0067016-t006">Table 6</xref>. All three clones are restricted by HLA-B alleles. The minimal epitopes recognized by EsxJ-specific D503 F9 and PE_PGRS42-specific D432 H8 are 11 and 9 aa in length, respectively. D432 D8 did not recognize any of all possible 8-, 9-, 10-, 11- and 12-mers within the 15-mer, PE9<sub>53–67</sub>, and therefore, a minimal epitope could not be determined. However, recognition of PE9<sub>53–67</sub> by D432 D8 was blocked by pan-human MHC Class I blocking antibody, W6/32, confirming the HLA-B restriction of this clone. Furthermore, D432 D8 recognized a second, independently synthesized PE9<sub>53–67</sub> peptide, suggesting that results with the original synthesized peptide were not due to recognition of a second, contaminating peptide. While the nested peptide approach is generally a productive means by which to identify minimal epitopes, we have been unsuccessful in a small minority (<5%) of epitopes recognized by human HIV-specific and Mtb-specific CD8<sup>+</sup> T cell clones <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>, <xref rid="pone.0067016-Lewinsohn6" ref-type="bibr">[24]</xref>, <xref rid="pone.0067016-Brodie1" ref-type="bibr">[37]</xref>.</p><table-wrap id="pone-0067016-t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0067016.t006</object-id><label>Table 6</label><caption><title>Summary of CD8<sup>+</sup> T cell epitopes identified.</title></caption><alternatives><graphic id="pone-0067016-t006-6" xlink:href="pone.0067016.t006"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Donor</td><td align="left" rowspan="1" colspan="1">Clone<xref ref-type="table-fn" rid="nt104">1</xref></td><td align="left" rowspan="1" colspan="1">Protein<xref ref-type="table-fn" rid="nt105">2</xref></td><td align="left" rowspan="1" colspan="1">HLA-Restricting Allele</td><td align="left" rowspan="1" colspan="1">Epitope Location</td><td align="left" rowspan="1" colspan="1">Epitope Sequence</td><td align="left" rowspan="1" colspan="1">Epitope-Specific T cells<xref ref-type="table-fn" rid="nt106">3</xref></td><td align="left" rowspan="1" colspan="1">V Beta Region</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">504</td><td align="left" rowspan="1" colspan="1">F9 (6)</td><td align="left" rowspan="1" colspan="1">EsxJ</td><td align="left" rowspan="1" colspan="1">B5701</td><td align="left" rowspan="1" colspan="1">24–34</td><td align="left" rowspan="1" colspan="1">QTVEDEARRMW</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">IND</td></tr><tr><td align="left" rowspan="1" colspan="1">432</td><td align="left" rowspan="1" colspan="1">D8 (1)</td><td align="left" rowspan="1" colspan="1">PE9</td><td align="left" rowspan="1" colspan="1">B3905</td><td align="left" rowspan="1" colspan="1">53–67</td><td align="left" rowspan="1" colspan="1">RLFNANAEEYHALSA</td><td align="left" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">432</td><td align="left" rowspan="1" colspan="1">H8 (1)</td><td align="left" rowspan="1" colspan="1">PE_PGRS42</td><td align="left" rowspan="1" colspan="1">B3514</td><td align="left" rowspan="1" colspan="1">48–56</td><td align="left" rowspan="1" colspan="1">SAAIAGLFG</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">7.1</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label>1</label><p>Number of sister clones is in parentheses.</p></fn><fn id="nt105"><label>2</label><p>TubercuList accession numbers are EsxJ (Rv1038c), PE9 (Rv1088), and PE_PGRS42 (2487c).</p></fn><fn id="nt106"><label>3</label><p>IFN-γ spot forming units per 250,000 CD8<sup>+</sup> T cells. IND, indeterminate.</p></fn></table-wrap-foot></table-wrap><p>To determine if epitopes defined were strongly recognized by CD8<sup>+</sup> T cells in persons from whom the clones were isolated, we determined ex vivo effector cell frequencies using CD8<sup>+</sup> T cells isolated from donor PBMCs and autologous DC pulsed with peptide as previously described <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>(<xref ref-type="table" rid="pone-0067016-t006">Table 6</xref>). CD8<sup>+</sup> T cells from D504 recognized EsxJ<sub>24–34</sub> at a frequency of 84 per 250,000 CD8<sup>+</sup> T cells. D432 CD8<sup>+</sup> T cells recognized PE9<sub>53–57</sub> and PE_PGRS42<sub>48–56</sub>, at frequencies of 94 and 78 per 250,000 CD8<sup>+</sup> T cells, respectively. Consistent with the strong ex vivo effector cell response to EsxJ<sub>24–34</sub>, multiple T cell clones recognizing this epitope were isolated from D504. We attempted to confirm the clonal relationship between daughter clones by TCR Vβ staining, however, the staining was indeterminate. The flow cytometric method used provides approximately 70% coverage of the normal human TCRVβ, thus this data is suggestive, though not definitive that the six EsxJ-specific D504 CD8<sup>+</sup> T cell clones represent daughter clones.</p></sec></sec><sec id="s4"><title>Discussion</title><p>We have used a T cell-centered approach to define novel TB antigens and epitopes <xref rid="pone.0067016-Lewinsohn2" ref-type="bibr">[10]</xref>, <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>, <xref rid="pone.0067016-Lewinsohn6" ref-type="bibr">[24]</xref>. Specifically, our first approach was to use T cell clones isolated from Mtb-infected individuals to screen a limited peptide library representing eight known CD4 antigens. Using this approach we were able to identify the antigen/epitopes recognized by many of the classically Ia-restricted Mtb-specific T cells clones isolated in our laboratory. We noted that these epitopes were strongly recognized by CD8<sup>+</sup> T cells in the persons from whom the T cell clones were isolated and predominantly restricted by HLA-B. Moreover, we noted that the majority of minimal epitopes were longer than nine amino acids. In considering a broader approach to identify the antigen(s) recognized by the remaining T cell clones, we noted that unlike a pathogen with a relatively small genome, such as HIV or hepatitis C virus, creating a peptide library representing the entire Mtb genome would be prohibitive both in terms of cost and labor. Therefore, we developed a weighting schema to select 10% of the Mtb proteome that we predicted would be enriched for CD8 antigens. This library was then screened with CD8<sup>+</sup> T cell clones with unknown antigen specificity. Using this approach, we identified three new CD8 antigens/epitopes recognized by Mtb-infected T cells that are not known CD4 antigens and hence could not have been detected using our more limited peptide library based upon known CD4 antigens. In addition, all three new CD8 epitopes are restricted by less common HLA-B alleles infrequently interrogated with peptide binding prediction algorithms and hence unlikely to have been revealed with these methods. Finally, strong ex vivo CD8<sup>+</sup> T cell effector responses were detected similar to our previous observations using a T cell-centered approach <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>.</p><p>Despite screening the peptide library with over 30 non-classically restricted Mtb-reactive CD8<sup>+</sup> T cell clones, we were unsuccessful in defining any non-classically restricted antigens. These MR1 <xref rid="pone.0067016-Gold1" ref-type="bibr">[14]</xref> and HLA-E <xref rid="pone.0067016-Heinzel1" ref-type="bibr">[34]</xref>, restricted CD8<sup>+</sup> T cell clones recognize protein antigens found within the Mtb cell wall, and we postulate may be either post-translationally modified or non-peptidic. By contrast, using the peptide library representing 10% of the Mtb proteome, in addition to the limited peptide library representing eight known CD4 antigens, we have now identified cognate antigens recognized by 51 of 56 of the HLA-Ia restricted CD8<sup>+</sup> T cell clones we have isolated. Furthermore, four of five of the clones for which the cognate antigen was not identified were derived from the same donor. Based our prior observations <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>, it is likely that these clones recognize less than four distinct antigens/epitopes. Hence, this represents a productive approach for novel discovery of classically restricted CD8 antigens. Identification of the antigen(s) recognized by the non-classically restricted CD8<sup>+</sup> T cell clones with unknown specificity may require distinct approaches such as an alternative proteomics approach and/or screening an Mtb library expressed in mycobacteria.</p><p>The definition of three more CD8 epitopes restricted by HLA-B alleles is consistent with our previous observations <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref> and further strengthens the evidence that TB CD8 antigens are preferentially restricted by HLA-B. The reasons for this predominance have not been delineated. However, we speculate that this bias could possibly be due to preferential binding of Mtb-derived peptides to HLA-B, selective upregulation of HLA-B with infection with Mtb, preferential recruitment of HLA-B alleles to the Mtb-containing phagosome <xref rid="pone.0067016-Grotzke2" ref-type="bibr">[38]</xref>, and/or selective interference with HLA-A processing and presentation by Mtb. We doubt that our cloning methodology is biased towards isolation of HLA-B- over HLA-A-restricted T cell clones, as using identical methodology we have not observed this skewing for vaccinia-, CMV-, and influenza-specific CD8<sup>+</sup> T cell clones (D. Lewinsohn, unpublished data and <xref rid="pone.0067016-Gold2" ref-type="bibr">[39]</xref>. These data are also consistent with data that suggested that HLA-B-restricted HIV-specific CD8<sup>+</sup> T cell responses predominated over HLA-A-restricted T cell responses in infected individuals, and were more closely linked with control of HIV viremia <xref rid="pone.0067016-Kiepiela1" ref-type="bibr">[40]</xref>. Hence, collective data support the hypothesis that HLA-B-restricted responses may be important for control of both bacterial and viral pathogens.</p><p>While the EsxJ family members have not been previously described as either CD4 or CD8 antigens, related ESAT-6, CFP-10, and some other ESAT-6 family members are known human CD4 antigens <xref rid="pone.0067016-Aagaard1" ref-type="bibr">[41]</xref> and ESAT-6 and CFP-10 are known CD8 antigens <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>. All of these are secreted antigens, which in animal models and humans have been shown to be more immunogenic than cell-associated antigens and in animal models are associated with protection <xref rid="pone.0067016-Reed1" ref-type="bibr">[23]</xref>, <xref rid="pone.0067016-Andersen1" ref-type="bibr">[28]</xref>–<xref rid="pone.0067016-Lambert1" ref-type="bibr">[31]</xref>. Our results further demonstrate the immunogenic potential of members of the PE/PPE family of mycobacterial proteins. The PE/PPE proteins are highly variable, unique to mycobacterial species, and comprise 4.2% of the Mtb genome (TubercuList, <ext-link ext-link-type="uri" xlink:href="http://genolist.pasteur.fr/TubercuList/">http://genolist.pasteur.fr/TubercuList/</ext-link>). Unlike ESAT-6 and CFP-10, EsxJ, PE9, and PE_PGRS42 are expressed in BCG (<ext-link ext-link-type="uri" xlink:href="http://www.uniprot.org">http://www.uniprot.org</ext-link>). Therefore, inclusion of these antigens in recent promising LTBI diagnostics which have increased specificity for Mtb infection based upon measurement of CD4<sup>+</sup> T cells responses to CFP-10 and ESAT-6 (QuantiFERON, Cellestis Corp and T-spot.TB, Oxford Immunotech), would unlikely increase the performances of these tests. However, these new antigens warrant further investigations as CD8<sup>+</sup> T cell based TB diagnostics and as candidates in inclusion of TB vaccine candidates. In this regard, we have previously demonstrated that CD8 responses to antigens found in both Mtb and environmental mycobacteria are strongly associated with infection with Mtb <xref rid="pone.0067016-Lewinsohn3" ref-type="bibr">[11]</xref>.</p><p>There are several significant infectious causes of morbidity and mortality for which vaccines have yet to be developed, and for which host immunity is critically dependent upon CD4<sup>+</sup> and/or CD8<sup>+</sup> T cell immunity <xref rid="pone.0067016-Lewinsohn1" ref-type="bibr">[1]</xref>. Several of these vaccine targets, including HSV, Mtb, <italic>Plasmodium</italic> sp., <italic>Chlamydia</italic> sp., and <italic>Leishmania</italic> sp. possess relatively large genomes, making whole genome screens of peptide libraries for T cell antigens relatively impractical. This integrated computational and proteomic screening approach for the identification of CD8 antigens could be applied to these other pathogens with large genome size. Moreover, such peptide libraries can be used to define the magnitude and breadth of ex vivo CD8<sup>+</sup> T effector cell responses. In this regard, current work is underway to screen our peptide library with CD8<sup>+</sup> T cells from Mtb-infected persons directly ex vivo to define novel CD8 antigens which are strongly and/or commonly recognized.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0067016.s001"><label>Table S1</label><caption><p><bold>List of genes included in the peptide library.</bold></p><p>(DOC)</p></caption><media xlink:href="pone.0067016.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We would like to acknowledge Roger Croteau for assistance with human subject protocols, Ervina Winata for technical assistance, and Dr. Karen Dobos, Colorado State University for providing proteomic data on Mtb cell-associated and secreted proteins.</p></ack><ref-list><title>References</title><ref id="pone.0067016-Lewinsohn1"><label>1</label><mixed-citation publication-type="journal"><name><surname>Lewinsohn</surname><given-names>DA</given-names></name>, <name><surname>Gold</surname><given-names>MC</given-names></name>, <name><surname>Lewinsohn</surname><given-names>DM</given-names></name> (<year>2011</year>) <article-title>Views of immunology: effector T cells</article-title>. <source>Immunol Rev</source><volume>240</volume>: <fpage>25</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">21349084</pub-id></mixed-citation></ref><ref id="pone.0067016-Day1"><label>2</label><mixed-citation publication-type="journal"><name><surname>Day</surname><given-names>CL</given-names></name>, <name><surname>Shea</surname><given-names>AK</given-names></name>, <name><surname>Altfeld</surname><given-names>MA</given-names></name>, <name><surname>Olson</surname><given-names>DP</given-names></name>, <name><surname>Buchbinder</surname><given-names>SP</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles</article-title>. <source>J Virol</source><volume>75</volume>: <fpage>6279</fpage>–<lpage>6291</lpage>.<pub-id pub-id-type="pmid">11413294</pub-id></mixed-citation></ref><ref id="pone.0067016-1"><label>3</label><mixed-citation publication-type="book">(2008) Global tuberculosis control: surveillance, planning, financing. WHO report 2008. Geneva, Switzerland.</mixed-citation></ref><ref id="pone.0067016-2"><label>4</label><mixed-citation publication-type="book">(2008) WHO vaccine-preventable diseases: monitoring system 2008 global summary. Geneva, Switzerland.</mixed-citation></ref><ref id="pone.0067016-Flynn1"><label>5</label><mixed-citation publication-type="journal"><name><surname>Flynn</surname><given-names>JL</given-names></name> (<year>2006</year>) <article-title>Lessons from experimental Mycobacterium tuberculosis infections</article-title>. <source>Microbes Infect</source><volume>8</volume>: <fpage>1179</fpage>–<lpage>1188</lpage>.<pub-id pub-id-type="pmid">16513383</pub-id></mixed-citation></ref><ref id="pone.0067016-Barnes1"><label>6</label><mixed-citation publication-type="journal"><name><surname>Barnes</surname><given-names>PF</given-names></name>, <name><surname>Bloch</surname><given-names>AB</given-names></name>, <name><surname>Davidson</surname><given-names>PT</given-names></name>, <name><surname>Snider</surname><given-names>DE</given-names><suffix>Jr</suffix></name> (<year>1991</year>) <article-title>Tuberculosis in patients with human immunodeficiency virus infection</article-title>. <source>N Engl J Med</source><volume>324</volume>: <fpage>1644</fpage>–<lpage>1650</lpage>.<pub-id pub-id-type="pmid">2030721</pub-id></mixed-citation></ref><ref id="pone.0067016-Oldstone1"><label>7</label><mixed-citation publication-type="journal"><name><surname>Oldstone</surname><given-names>MB</given-names></name> (<year>1994</year>) <article-title>The role of cytotoxic T lymphocytes in infectious disease: history, criteria, and state of the art</article-title>. <source>Curr Top Microbiol Immmunol</source><volume>189</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</mixed-citation></ref><ref id="pone.0067016-Woodworth1"><label>8</label><mixed-citation publication-type="journal"><name><surname>Woodworth</surname><given-names>JS</given-names></name>, <name><surname>Behar</surname><given-names>SM</given-names></name> (<year>2006</year>) <article-title>Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity</article-title>. <source>Crit Rev Immunol</source><volume>26</volume>: <fpage>317</fpage>–<lpage>352</lpage>.<pub-id pub-id-type="pmid">17073557</pub-id></mixed-citation></ref><ref id="pone.0067016-Lalvani1"><label>9</label><mixed-citation publication-type="journal"><name><surname>Lalvani</surname><given-names>A</given-names></name>, <name><surname>Brookes</surname><given-names>R</given-names></name>, <name><surname>Wilkinson</surname><given-names>RJ</given-names></name>, <name><surname>Malin</surname><given-names>AS</given-names></name>, <name><surname>Pathan</surname><given-names>AA</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>95</volume>: <fpage>270</fpage>–<lpage>275</lpage>.<pub-id pub-id-type="pmid">9419365</pub-id></mixed-citation></ref><ref id="pone.0067016-Lewinsohn2"><label>10</label><mixed-citation publication-type="journal"><name><surname>Lewinsohn</surname><given-names>DM</given-names></name>, <name><surname>Zhu</surname><given-names>L</given-names></name>, <name><surname>Madison</surname><given-names>VJ</given-names></name>, <name><surname>Dillon</surname><given-names>DC</given-names></name>, <name><surname>Fling</surname><given-names>SP</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity</article-title>. <source>J Immunol</source><volume>166</volume>: <fpage>439</fpage>–<lpage>446</lpage>.<pub-id pub-id-type="pmid">11123322</pub-id></mixed-citation></ref><ref id="pone.0067016-Lewinsohn3"><label>11</label><mixed-citation publication-type="journal"><name><surname>Lewinsohn</surname><given-names>DA</given-names></name>, <name><surname>Winata</surname><given-names>E</given-names></name>, <name><surname>Swarbrick</surname><given-names>GM</given-names></name>, <name><surname>Tanner</surname><given-names>KE</given-names></name>, <name><surname>Cook</surname><given-names>MS</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B</article-title>. <source>PLoS Pathog</source><volume>3</volume>: <fpage>1240</fpage>–<lpage>1249</lpage>.<pub-id pub-id-type="pmid">17892322</pub-id></mixed-citation></ref><ref id="pone.0067016-Cho1"><label>12</label><mixed-citation publication-type="journal"><name><surname>Cho</surname><given-names>S</given-names></name>, <name><surname>Mehra</surname><given-names>V</given-names></name>, <name><surname>Thoma-Uszynski</surname><given-names>S</given-names></name>, <name><surname>Stenger</surname><given-names>S</given-names></name>, <name><surname>Serbina</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>97</volume>: <fpage>12210</fpage>–<lpage>12215</lpage>.<pub-id pub-id-type="pmid">11035787</pub-id></mixed-citation></ref><ref id="pone.0067016-Grotzke1"><label>13</label><mixed-citation publication-type="journal"><name><surname>Grotzke</surname><given-names>JE</given-names></name>, <name><surname>Lewinsohn</surname><given-names>DM</given-names></name> (<year>2005</year>) <article-title>Role of CD8+ T lymphocytes in control of Mycobacterium tuberculosis infection</article-title>. <source>Microbes Infect</source><volume>7</volume>: <fpage>776</fpage>–<lpage>788</lpage>.<pub-id pub-id-type="pmid">15823514</pub-id></mixed-citation></ref><ref id="pone.0067016-Gold1"><label>14</label><mixed-citation publication-type="journal"><name><surname>Gold</surname><given-names>MC</given-names></name>, <name><surname>Cerri</surname><given-names>S</given-names></name>, <name><surname>Smyk-Pearson</surname><given-names>S</given-names></name>, <name><surname>Cansler</surname><given-names>ME</given-names></name>, <name><surname>Vogt</surname><given-names>TM</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Human mucosal associated invariant T cells detect bacterially infected cells</article-title>. <source>PLoS Biol</source><volume>8</volume>: <fpage>e1000407</fpage>.<pub-id pub-id-type="pmid">20613858</pub-id></mixed-citation></ref><ref id="pone.0067016-Lewinsohn4"><label>15</label><mixed-citation publication-type="journal"><name><surname>Lewinsohn</surname><given-names>DM</given-names></name>, <name><surname>Bement</surname><given-names>TT</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Lynch</surname><given-names>DH</given-names></name>, <name><surname>Grabstein</surname><given-names>KH</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms</article-title>. <source>J Immunol</source><volume>160</volume>: <fpage>2374</fpage>–<lpage>2379</lpage>.<pub-id pub-id-type="pmid">9498779</pub-id></mixed-citation></ref><ref id="pone.0067016-Lewinsohn5"><label>16</label><mixed-citation publication-type="journal"><name><surname>Lewinsohn</surname><given-names>DA</given-names></name>, <name><surname>Heinzel</surname><given-names>AS</given-names></name>, <name><surname>Gardner</surname><given-names>JM</given-names></name>, <name><surname>Zhu</surname><given-names>L</given-names></name>, <name><surname>Alderson</surname><given-names>MR</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells</article-title>. <source>Am J Respir Crit Care Med</source><volume>168</volume>: <fpage>1346</fpage>–<lpage>1352</lpage>.<pub-id pub-id-type="pmid">12969871</pub-id></mixed-citation></ref><ref id="pone.0067016-Hoang1"><label>17</label><mixed-citation publication-type="journal"><name><surname>Hoang</surname><given-names>TT</given-names></name>, <name><surname>Nansen</surname><given-names>A</given-names></name>, <name><surname>Roy</surname><given-names>S</given-names></name>, <name><surname>Billeskov</surname><given-names>R</given-names></name>, <name><surname>Aagaard</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis</article-title>. <source>PLoS One</source><volume>4</volume>: <fpage>e5928</fpage>.<pub-id pub-id-type="pmid">19529765</pub-id></mixed-citation></ref><ref id="pone.0067016-vanPinxteren1"><label>18</label><mixed-citation publication-type="journal"><name><surname>van Pinxteren</surname><given-names>LA</given-names></name>, <name><surname>Cassidy</surname><given-names>JP</given-names></name>, <name><surname>Smedegaard</surname><given-names>BH</given-names></name>, <name><surname>Agger</surname><given-names>EM</given-names></name>, <name><surname>Andersen</surname><given-names>P</given-names></name> (<year>2000</year>) <article-title>Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells</article-title>. <source>Eur J Immunol</source><volume>30</volume>: <fpage>3689</fpage>–<lpage>3698</lpage>.<pub-id pub-id-type="pmid">11169412</pub-id></mixed-citation></ref><ref id="pone.0067016-Ordway1"><label>19</label><mixed-citation publication-type="journal"><name><surname>Ordway</surname><given-names>D</given-names></name>, <name><surname>Higgins</surname><given-names>DM</given-names></name>, <name><surname>Sanchez-Campillo</surname><given-names>J</given-names></name>, <name><surname>Spencer</surname><given-names>JS</given-names></name>, <name><surname>Henao-Tamayo</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>XCL1 (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infection with Mycobacterium tuberculosis negatively affects production of IFN-gamma by CD4 T cells and participates in granuloma stability</article-title>. <source>J Leukoc Biol</source><volume>82</volume>: <fpage>1221</fpage>–<lpage>1229</lpage>.<pub-id pub-id-type="pmid">17699612</pub-id></mixed-citation></ref><ref id="pone.0067016-Mogues1"><label>20</label><mixed-citation publication-type="journal"><name><surname>Mogues</surname><given-names>T</given-names></name>, <name><surname>Goodrich</surname><given-names>ME</given-names></name>, <name><surname>Ryan</surname><given-names>L</given-names></name>, <name><surname>LaCourse</surname><given-names>R</given-names></name>, <name><surname>North</surname><given-names>RJ</given-names></name> (<year>2001</year>) <article-title>The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice</article-title>. <source>J Exp Med</source><volume>193</volume>: <fpage>271</fpage>–<lpage>280</lpage>.<pub-id pub-id-type="pmid">11157048</pub-id></mixed-citation></ref><ref id="pone.0067016-Chen1"><label>21</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>CY</given-names></name>, <name><surname>Huang</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>RC</given-names></name>, <name><surname>Shen</surname><given-names>L</given-names></name>, <name><surname>Zeng</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>A critical role for CD8 T cells in a nonhuman primate model of tuberculosis</article-title>. <source>PLoS Pathog</source><volume>5</volume>: <fpage>e1000392</fpage>.<pub-id pub-id-type="pmid">19381260</pub-id></mixed-citation></ref><ref id="pone.0067016-Louise1"><label>22</label><mixed-citation publication-type="journal"><name><surname>Louise</surname><given-names>R</given-names></name>, <name><surname>Skjot</surname><given-names>V</given-names></name>, <name><surname>Agger</surname><given-names>EM</given-names></name>, <name><surname>Andersen</surname><given-names>P</given-names></name> (<year>2001</year>) <article-title>Antigen discovery and tuberculosis vaccine development in the post-genomic era</article-title>. <source>Scand J Infect Dis</source><volume>33</volume>: <fpage>643</fpage>–<lpage>647</lpage>.<pub-id pub-id-type="pmid">11669220</pub-id></mixed-citation></ref><ref id="pone.0067016-Reed1"><label>23</label><mixed-citation publication-type="journal"><name><surname>Reed</surname><given-names>S</given-names></name>, <name><surname>Lobet</surname><given-names>Y</given-names></name> (<year>2005</year>) <article-title>Tuberculosis vaccine development; from mouse to man</article-title>. <source>Microbes Infect</source><volume>7</volume>: <fpage>922</fpage>–<lpage>931</lpage>.<pub-id pub-id-type="pmid">15935717</pub-id></mixed-citation></ref><ref id="pone.0067016-Lewinsohn6"><label>24</label><mixed-citation publication-type="journal"><name><surname>Lewinsohn</surname><given-names>DA</given-names></name>, <name><surname>Lines</surname><given-names>RA</given-names></name>, <name><surname>Lewinsohn</surname><given-names>DM</given-names></name> (<year>2002</year>) <article-title>Human dendritic cells presenting adenovirally expressed antigen elicit Mtb-specific CD8+ T cells</article-title>. <source>Am J Respir Crit Care Med</source><volume>166</volume>: <fpage>843</fpage>–<lpage>848</lpage>.<pub-id pub-id-type="pmid">12231495</pub-id></mixed-citation></ref><ref id="pone.0067016-Schnappinger1"><label>25</label><mixed-citation publication-type="journal"><name><surname>Schnappinger</surname><given-names>D</given-names></name>, <name><surname>Ehrt</surname><given-names>S</given-names></name>, <name><surname>Voskuil</surname><given-names>MI</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Mangan</surname><given-names>JA</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment</article-title>. <source>J Exp Med</source><volume>198</volume>: <fpage>693</fpage>–<lpage>704</lpage>.<pub-id pub-id-type="pmid">12953091</pub-id></mixed-citation></ref><ref id="pone.0067016-McDermott1"><label>26</label><mixed-citation publication-type="journal"><name><surname>McDermott</surname><given-names>AB</given-names></name>, <name><surname>Koup</surname><given-names>RA</given-names></name> (<year>2012</year>) <article-title>CD8(+) T cells in preventing HIV infection and disease</article-title>. <source>AIDS</source><volume>26</volume>: <fpage>1281</fpage>–<lpage>1292</lpage>.<pub-id pub-id-type="pmid">22441256</pub-id></mixed-citation></ref><ref id="pone.0067016-Moss1"><label>27</label><mixed-citation publication-type="journal"><name><surname>Moss</surname><given-names>P</given-names></name>, <name><surname>Khan</surname><given-names>N</given-names></name> (<year>2004</year>) <article-title>CD8(+) T-cell immunity to cytomegalovirus</article-title>. <source>Hum Immunol</source><volume>65</volume>: <fpage>456</fpage>–<lpage>464</lpage>.<pub-id pub-id-type="pmid">15172445</pub-id></mixed-citation></ref><ref id="pone.0067016-Andersen1"><label>28</label><mixed-citation publication-type="journal"><name><surname>Andersen</surname><given-names>P</given-names></name> (<year>1994</year>) <article-title>Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins</article-title>. <source>Infect Immun</source><volume>62</volume>: <fpage>2536</fpage>–<lpage>2544</lpage>.<pub-id pub-id-type="pmid">7910595</pub-id></mixed-citation></ref><ref id="pone.0067016-Horwitz1"><label>29</label><mixed-citation publication-type="journal"><name><surname>Horwitz</surname><given-names>MA</given-names></name>, <name><surname>Harth</surname><given-names>G</given-names></name>, <name><surname>Dillon</surname><given-names>BJ</given-names></name>, <name><surname>Maslesa-Galic</surname><given-names>S</given-names></name> (<year>2000</year>) <article-title>Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>97</volume>: <fpage>13853</fpage>–<lpage>13858</lpage>.<pub-id pub-id-type="pmid">11095745</pub-id></mixed-citation></ref><ref id="pone.0067016-Roberts1"><label>30</label><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>AD</given-names></name>, <name><surname>Sonnenberg</surname><given-names>MG</given-names></name>, <name><surname>Ordway</surname><given-names>DJ</given-names></name>, <name><surname>Furney</surname><given-names>SK</given-names></name>, <name><surname>Brennan</surname><given-names>PJ</given-names></name>, <etal>et al</etal> (<year>1995</year>) <article-title>Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis</article-title>. <source>Immunology</source><volume>85</volume>: <fpage>502</fpage>–<lpage>508</lpage>.<pub-id pub-id-type="pmid">7558141</pub-id></mixed-citation></ref><ref id="pone.0067016-Lambert1"><label>31</label><mixed-citation publication-type="book">Lambert PH, Hawkridge T, Hanekom WA (2009) New vaccines against tuberculosis. Clin Chest Med 30: : 811–826, x.</mixed-citation></ref><ref id="pone.0067016-Betts1"><label>32</label><mixed-citation publication-type="journal"><name><surname>Betts</surname><given-names>MR</given-names></name>, <name><surname>Ambrozak</surname><given-names>DR</given-names></name>, <name><surname>Douek</surname><given-names>DC</given-names></name>, <name><surname>Bonhoeffer</surname><given-names>S</given-names></name>, <name><surname>Brenchley</surname><given-names>JM</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection</article-title>. <source>J Virol</source><volume>75</volume>: <fpage>11983</fpage>–<lpage>11991</lpage>.<pub-id pub-id-type="pmid">11711588</pub-id></mixed-citation></ref><ref id="pone.0067016-Lewinsohn7"><label>33</label><mixed-citation publication-type="journal"><name><surname>Lewinsohn</surname><given-names>DM</given-names></name>, <name><surname>Briden</surname><given-names>AL</given-names></name>, <name><surname>Reed</surname><given-names>SG</given-names></name>, <name><surname>Grabstein</surname><given-names>KH</given-names></name>, <name><surname>Alderson</surname><given-names>MR</given-names></name> (<year>2000</year>) <article-title>Mycobacterium tuberculosis-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction</article-title>. <source>J Immunol</source><volume>165</volume>: <fpage>925</fpage>–<lpage>930</lpage>.<pub-id pub-id-type="pmid">10878367</pub-id></mixed-citation></ref><ref id="pone.0067016-Heinzel1"><label>34</label><mixed-citation publication-type="journal"><name><surname>Heinzel</surname><given-names>AS</given-names></name>, <name><surname>Grotzke</surname><given-names>JE</given-names></name>, <name><surname>Lines</surname><given-names>RA</given-names></name>, <name><surname>Lewinsohn</surname><given-names>DA</given-names></name>, <name><surname>McNabb</surname><given-names>AL</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells</article-title>. <source>J Exp Med</source><volume>196</volume>: <fpage>1473</fpage>–<lpage>1481</lpage>.<pub-id pub-id-type="pmid">12461082</pub-id></mixed-citation></ref><ref id="pone.0067016-Riddell1"><label>35</label><mixed-citation publication-type="journal"><name><surname>Riddell</surname><given-names>SR</given-names></name>, <name><surname>Watanabe</surname><given-names>KS</given-names></name>, <name><surname>Goodrich</surname><given-names>JM</given-names></name>, <name><surname>Li</surname><given-names>CR</given-names></name>, <name><surname>Agha</surname><given-names>ME</given-names></name>, <etal>et al</etal> (<year>1992</year>) <article-title>Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones</article-title>. <source>Science</source><volume>257</volume>: <fpage>238</fpage>–<lpage>241</lpage>.<pub-id pub-id-type="pmid">1352912</pub-id></mixed-citation></ref><ref id="pone.0067016-Romani1"><label>36</label><mixed-citation publication-type="journal"><name><surname>Romani</surname><given-names>N</given-names></name>, <name><surname>Gruner</surname><given-names>S</given-names></name>, <name><surname>Brang</surname><given-names>D</given-names></name>, <name><surname>Kampgen</surname><given-names>E</given-names></name>, <name><surname>Lenz</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>1994</year>) <article-title>Proliferating dendritic cell progenitors in human blood</article-title>. <source>J Exp Med</source><volume>180</volume>: <fpage>83</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">8006603</pub-id></mixed-citation></ref><ref id="pone.0067016-Brodie1"><label>37</label><mixed-citation publication-type="journal"><name><surname>Brodie</surname><given-names>SJ</given-names></name>, <name><surname>Lewinsohn</surname><given-names>DA</given-names></name>, <name><surname>Patterson</surname><given-names>BK</given-names></name>, <name><surname>Jiyamapa</surname><given-names>D</given-names></name>, <name><surname>Krieger</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>In vivo migration and function of transferred HIV-1-specific cytotoxic T cells Nat Med</article-title>. <volume>5</volume>: <fpage>34</fpage>–<lpage>41</lpage>.</mixed-citation></ref><ref id="pone.0067016-Grotzke2"><label>38</label><mixed-citation publication-type="journal"><name><surname>Grotzke</surname><given-names>JE</given-names></name>, <name><surname>Harriff</surname><given-names>MJ</given-names></name>, <name><surname>Siler</surname><given-names>AC</given-names></name>, <name><surname>Nolt</surname><given-names>D</given-names></name>, <name><surname>Delepine</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>The Mycobacterium tuberculosis phagosome is a HLA-I processing competent organelle</article-title>. <source>PLoS Pathog</source><volume>5</volume>: <fpage>e1000374</fpage>.<pub-id pub-id-type="pmid">19360129</pub-id></mixed-citation></ref><ref id="pone.0067016-Gold2"><label>39</label><mixed-citation publication-type="journal"><name><surname>Gold</surname><given-names>MC</given-names></name>, <name><surname>Robinson</surname><given-names>TL</given-names></name>, <name><surname>Cook</surname><given-names>MS</given-names></name>, <name><surname>Byrd</surname><given-names>LK</given-names></name>, <name><surname>Ehlinger</surname><given-names>HD</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Human neonatal dendritic cells are competent in MHC class I antigen processing and presentation</article-title>. <source>PLoS ONE</source><volume>2</volume>: <fpage>e957</fpage>.<pub-id pub-id-type="pmid">17895997</pub-id></mixed-citation></ref><ref id="pone.0067016-Kiepiela1"><label>40</label><mixed-citation publication-type="journal"><name><surname>Kiepiela</surname><given-names>P</given-names></name>, <name><surname>Leslie</surname><given-names>AJ</given-names></name>, <name><surname>Honeyborne</surname><given-names>I</given-names></name>, <name><surname>Ramduth</surname><given-names>D</given-names></name>, <name><surname>Thobakgale</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA</article-title>. <source>Nature</source><volume>432</volume>: <fpage>769</fpage>–<lpage>775</lpage>.<pub-id pub-id-type="pmid">15592417</pub-id></mixed-citation></ref><ref id="pone.0067016-Aagaard1"><label>41</label><mixed-citation publication-type="journal"><name><surname>Aagaard</surname><given-names>C</given-names></name>, <name><surname>Dietrich</surname><given-names>J</given-names></name>, <name><surname>Doherty</surname><given-names>M</given-names></name>, <name><surname>Andersen</surname><given-names>P</given-names></name> (<year>2009</year>) <article-title>TB vaccines: current status and future perspectives</article-title>. <source>Immunol Cell Biol</source><volume>87</volume>: <fpage>279</fpage>–<lpage>286</lpage>.<pub-id pub-id-type="pmid">19350048</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001078 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001078 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |